NO - Besoin d'assistance

Observational epidemiological surveys (WG 3) page 60
_________________________________________________________________________________________
Table 34 Large (>1000) randomized clinical trials on vitamin E with and cardiovascular diseases
Authors
(year)
(ATBC, 1994)
Virtamo et al.,
(1998)
Blot et al.,
(1993)
Stephens et al.,
(1996)
GISSI Prev
Invest, 1999
HOPES, 2000
The HOPES
investigators,
2000
country, cases, M or
F, age
(Follow-up duration)
ATBC, Finland
29 133
M smokers, 50-59
6.1 yr
Chinese Cancer
Prevention study
29 584
CHAOS, UK
2002 patients with
angiogenic evidence
of CVD,
M+F
2 yr
Italy, 11234 patients
with recent MI, 3.5
years
Canada, 2545 W, 6996
M
high risk
4.5 years
outcome treatment OR, comparison group,
CI,
Total
mortalily
from CVD
Total
mortalily
Nonfatal MI
and deaths
from CHD
death, non
fatal MI,
stroke
MI, stroke,
dath CVD
50 mg a-tocopherol
acetate, 20 mg betacarotene
30 mg vit E suppl +
15mg β-carotene 50 µg
Se
400 or 800 IU vit E or
placebo
300mg vit E/ placebo
p trend
Remarks
OR=0.90 (0.75-1.08) Marginal effect of
suppl. in vit E on
CVD in male
smokers
OR= 0.90 (0.76-1.07)
OR=0.53 (0.34-0.83)
p 0.005
CV death: 0.94 (0.81-1.10)
400IU/day 1.05 (0.95-1.16)
no trend
Siginificant
reduction in major
CV events: no effect
on CV deaths and
all-cause mortality
n-3 PUFA 0.78
(0.65-0.92)